| Date Filed | Type | Description |
| 09/12/2018 |
3
| McManigle Mark Drew (Chief Liquidating Officer) has filed a Form 3 on Anthera Pharmaceuticals Inc |
| 07/30/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/27/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
RW
| Form RW - Registration Withdrawal Request: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/20/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/17/2018 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 07/09/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 06/27/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
| 06/27/2018 |
GN
| Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets |
| 06/18/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/30/2018 |
8-K
| Other Events |
| 05/23/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 05/15/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 05/04/2018 |
GN
| New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, Anthera Pharmaceuticals, and Alexandria Real Estate Equities — Factors of Influence, Major Initiatives and Sustained Production |
|